Umbilical cord blood transplantation with HSC835
Phase 1/2Withdrawn 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inherited Metabolic Disorders IMD
Conditions
Inherited Metabolic Disorders IMD
Trial Timeline
Oct 10, 2017 → May 18, 2020
NCT ID
NCT02715505About Umbilical cord blood transplantation with HSC835
Umbilical cord blood transplantation with HSC835 is a phase 1/2 stage product being developed by Novartis for Inherited Metabolic Disorders IMD. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02715505. Target conditions include Inherited Metabolic Disorders IMD.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02715505 | Phase 1/2 | Withdrawn |
Competing Products
4 competing products in Inherited Metabolic Disorders IMD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Cysteamine Bitartrate | Amgen | Phase 2 | 51 |
| PF-05089771 + Placebo | Pfizer | Phase 2 | 51 |
| BIIB074 + Placebo | Biogen | Phase 2 | 49 |
| Vatiquinone | PTC Therapeutics | Phase 3 | 74 |